摘要:目的:探讨新生儿缺氧缺血性脑病(HIE)的CT表现与临床分析。方法:对54例HIE患儿的CT表现及临床特点进行回顾性分析。结果:本组临床分度为轻度21例,占38.9％(21/54);中度24例,占44.4％(24/54);重度9例,占16.7％(9/54)。CT分度为轻度25例,占46.3%(25/54);中度18例,占33.3%(18/54);重度11例,占20.4%(11/54)。结论:CT对明确HIE的范围、动态观察病情变化,对临床早期干预治疗,降低后遗症有积极作用。Abstract: Objective: To explore the neonatal hypoxic ischemic encephalopathy (HIE) of CT findings and clinical analysis.Methods:Children of the 54 cases of HIE and clinical performance characteristics of CT were retrospectively analyzed.Results:Clinical subgroup 21 cases of mild degree, accounting for 38.9% (21/54); 24 cases of moderate, accounting for 44.4% (24/54); 9 cases of severe, accounting for 16.7% (9 / 54). CT at 25 cases of mild degree, accounting for 46.3% (25/54); 18 cases of moderate, accounting for 33.3% (18/54); 11 cases of severe, accounting for 20.4% (11/54).Conclusion:CT of the scope of HIE clear, dynamic observation of the disease changes in the clinical treatment of early intervention to reduce the aftereffects have a positive effect.
ObjectiveTo summarize the clinical manifestations, basic diseases, imaging features, drug sensitivity results and recovery of Mycobacterium Kansasii pulmonary disease patients to enhance understanding of the disease. Methods The clinical data of 116 patients with Mycobacterium Kansas pulmonary disease diagnosed in Guangzhou chest hospital from January 2019 to September 2024 were analyzed retrospectively. Results The 116 patients with Mycobacterium kansasensei lung disease were 67 males and 49 females, aged 27 to 92 years, with clinical manifestations of cough and sputum (102 cases) and hemoptysis (48 cases) as the predominant symptoms. There were 98 cases with history of bronchiectasis, 8 cases with cancer,18 cases with cardiovascular disease, 22 cases with chronic obstructive pulmonary disease, 10 cases with diabetes mellitus, 9 cases with rheumatoid immune system disease, 5 cases with pulmonary aspergillus infection, 2 cases with asthma, and 10 cases without underlying disease. All of them had lung shadows on imaging, including 30 cases with simple bronchodilatation manifestation, 48 cases with bronchodilatation combined with cavitation, 10 cases with patchy streak shadow, 18 cases with patchy streak shadow combined with cavitation, and 10 cases with nodules combined with cavitation. The results of drug sensitivity showed that the resistance rate of more than 50% was isoniazid (89.66%), streptomycin (75.87%), amikacin (72.41%), and isoniazid para-aminosalicylate (Likely Lung Disease) (56.90%); while the sensitivity rate of more than 50% was rifabutin (100%), moxifloxacin (94.83%), rifampicin (93.10%), prothioisonicotinamide ( 91.38%), levofloxacin (89.66%), ethambutol (84.48%), and linezolid (79.31%). 76 of the remaining 98 of 116 patients had negative sputum cultures within 1 year, with the exception of 12 who were left untreated and 6 who did not complete treatment. The 116 patients with Mycobacterium kansasensei lung disease presented with chronic cough, sputum, and hemoptysis, and most of them were combined with structural lung diseases such as bronchiectasis, or with underlying diseases such as chronic obstructive pulmonary disease and diabetes mellitus. Imaging features show pulmonary shadows. Moreover, Mycobacterium kansasii shows high sensitivity to most conventional antituberculosis drugs, which may result in a higher cure rate compared with other types of nontuberculous mycobacterial lung disease. Therefore, timely and well-conducted strain identification and drug sensitivity testing are essential for the development of a targeted treatment program that can significantly improve patient outcomes. Conclusions Clinical manifestations of 116 patients with Mycobacterium kansasense lung disease were characterized by chronic cough, sputum and hemoptysis, which were mostly combined with structural lung diseases such as bronchiectasis. The imaging features show pulmonary shadows. Mycobacterium kansasii exhibits a higher sensitivity rate to most conventional anti-tuberculosis drugs, which may result in a higher cure rate in treatment compared to other types of nontuberculous mycobacterial lung diseases. Therefore, timely and comprehensive species identification and drug susceptibility testing are crucial for formulating targeted treatment regimens, which can significantly improve patients' treatment outcomes.